|
|
|
|
|
HONG KONG, July 21, 2020 - (ACN Newswire) - Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing oncology and autoimmune therapeutics, announced that the new drug application (NDA) for Geptanolimab, a novel PD-1 mAb drug candidate, has been accepted by the National Medical Products Administration ("NMPA") for the treatment of Peripheral T cell Lymphoma (PTCL).
On the same day, Genor Biopharma announced the appointment of Mr. CHEN Wende as Chief Operation Officer. In this role, Mr. CHEN will oversee commercialization and prepare for launches of late-stage drug candidates.
Mr. CHEN brings over 20 years of experience in biopharmaceutical industry, focusing on sales and marketing and business operation at Roche, AstraZeneca, and Pfizer in China. Mr. CHEN was most recently Chief Commercial Officer at a well-known biotech company. Before that, Mr. CHEN served as Vice President at Roche China, overseeing Corporate Affairs, Market Access and Channel Management for a number of key drugs including Herceptin, MabThera, Avastin, Tarceva and Zelboraf. Mr. CHEN also served as Senior Vice President at AstraZeneca from 2010 and as Senior Sales Director at Pfizer from 2000.
"We are excited to appoint Mr. CHEN as COO of Genor Biopharma. We are looking to file NDAs for a number of our late-stage drug candidates in the near term," commented Dr. GUO, Chief Executive Officer of Genor Biopharma, "With over 20 years of experience in drug commercialization and deep insight of the landscape, Mr. CHEN will build our in-house commercialization team and lead our drug launches with differentiated strategy and drive our transformation into a biopharma company."
About JHBP (CY) Holdings Limited ("Genor Biopharma")
Established in December 2007, JHBP (CY) Holdings Limited is a biopharmaceutical powerhouse focusing on developing and commercializing oncology and autoimmune drugs. The Company has been strategically focused on major therapeutic areas with substantial unmet medical needs. At present, the Company has more than 10 drug candidates, 10 of which have entered the clinical development stage. The Company's pipeline products are mainly deployed in the field of cancer and other major diseases and have established a series of mature technology platforms in antibody drug research, development and manufacturing to serve patients in China and around the world. The Company's leadership team boasts more than 20 years of industry experience in global biopharmaceutical companies such as Pfizer, Merck, Amgen and AbbVie with proven track record and a well-balanced combination of expertise. The Company currently has around 400 employees across 3 sites in China - Shanghai Zhangjiang, Yunnan Yuxi, and Beijing office, as well as lab in South San Francisco, US, among which 80% are R&D and clinical specialists.
Topic: Press release summary
Source: Genor Biopharma
Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
The Tomorrow Company Launches With a Bold Mandate to Build the Infrastructure Layer of the AI-Native Financial Era.
Mar 2, 2026 08:06 HKT/SGT
|
|
|
CALB (3931.HK) Announced a Positive Profit Alert
Feb 28, 2026 11:43 HKT/SGT
|
|
|
Unisound U1-OCR: The First Industrial-Grade Document Intelligence Foundation Model, Ushering in the OCR 3.0 Era
Feb 28, 2026 09:00 HKT/SGT
|
|
|
NEC Strengthens Multi-Vendor Optical Network Solutions with New TIP-Certified Phoenix Hardware Lineup
Friday, February 27, 2026 5:50:00 PM
|
|
|
NEC Demonstrates Agentic AI-Driven Autonomous Network Operations in Collaboration with AWS
Friday, February 27, 2026 4:31:00 PM
|
|
|
Mitsubishi Heavy Industries Compressor Acquires Swiss Rotating Equipment Maintenance Company AST Turbo AG
Friday, February 27, 2026 4:23:00 PM
|
|
|
NEC Strengthens Its Edge Portfolio for the 6G Era, Enabling Efficient Edge Deployment and Integration with Cloud Services
Friday, February 27, 2026 11:24:00 AM
|
|
|
Fujitsu POS solution enhances customer experience at Hankyu Hanshin Department Stores
Friday, February 27, 2026 11:03:00 AM
|
|
|
Casa Minerals Announces 2026 Aggressive Exploration Plans for Congress Gold Mine and Arsenault Projects
Feb 26, 2026 21:59 HKT/SGT
|
|
|
Mitomo Semicon Engineering to Change Company Name
Thursday, February 26, 2026 9:00:00 PM
|
|
|
|
|
More Press release >> |
|
 |
|
 |
|
